<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>Clinical Trials</title>

<script src="site_libs/header-attrs-2.25/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.13.2/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<script src="site_libs/navigation-1.1/codefolding.js"></script>
<link href="site_libs/highlightjs-9.12.0/default.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<script src="site_libs/htmlwidgets-1.6.3/htmlwidgets.js"></script>
<script src="site_libs/plotly-binding-4.10.3/plotly.js"></script>
<script src="site_libs/typedarray-0.1/typedarray.min.js"></script>
<link href="site_libs/crosstalk-1.2.1/css/crosstalk.min.css" rel="stylesheet" />
<script src="site_libs/crosstalk-1.2.1/js/crosstalk.min.js"></script>
<link href="site_libs/plotly-htmlwidgets-css-2.11.1/plotly-htmlwidgets.css" rel="stylesheet" />
<script src="site_libs/plotly-main-2.11.1/plotly-latest.min.js"></script>
<link href="site_libs/font-awesome-6.4.2/css/all.min.css" rel="stylesheet" />
<link href="site_libs/font-awesome-6.4.2/css/v4-shims.min.css" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->
<style type="text/css">
.code-folding-btn { margin-bottom: 4px; }
</style>



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Home</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="Report.html">Report</a>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="Introduction.html">Introduction</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Analysis
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="Data.html">Data Sources</a>
    </li>
    <li>
      <a href="EDA.html">Exploratory Analysis</a>
    </li>
    <li>
      <a href="Preliminary_analysis.html">Preliminary Analysis</a>
    </li>
  </ul>
</li>
<li>
  <a href="Model.html">Model</a>
</li>
<li>
  <a href="Clinical_trials.html">Clinical Trials</a>
</li>
<li>
  <a href="Conclusion.html">Conclusion</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Shiny
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://yigebian.shinyapps.io/Demographic_shiny/">Demographic</a>
    </li>
    <li>
      <a href="https://yigebian.shinyapps.io/ClinicalTrials_shiny/">Clinical Trials</a>
    </li>
  </ul>
</li>
<li>
  <a href="mailto:&lt;yb2591@cumc.columbia.edu&gt;">
    <span class="fa fa-envelope fa-lg"></span>
     
  </a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-github fa-lg"></span>
     
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://github.com/MiaYum/Alzheimers_Disease_New_Hope">Website Repository</a>
    </li>
    <li>
      <a href="https://github.com/YigeBian/Alzheimers_Disease_New_Hope_Shiny">Shiny Repository</a>
    </li>
  </ul>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">

<div class="btn-group pull-right float-right">
<button type="button" class="btn btn-default btn-xs btn-secondary btn-sm dropdown-toggle" data-toggle="dropdown" data-bs-toggle="dropdown" aria-haspopup="true" aria-expanded="false"><span>Code</span> <span class="caret"></span></button>
<ul class="dropdown-menu dropdown-menu-right" style="min-width: 50px;">
<li><a id="rmd-show-all-code" href="#">Show All Code</a></li>
<li><a id="rmd-hide-all-code" href="#">Hide All Code</a></li>
</ul>
</div>



<h1 class="title toc-ignore">Clinical Trials</h1>

</div>


<pre class="r"><code># Function to tidy Donanemab results
combine_mean_sd = function(df, group = &quot;&quot;){
  
  n = df |&gt; filter(str_detect(group, &quot;Low/medium tau&quot;)) |&gt; pull(sample_size) # number in group 1
  m =  df |&gt; filter(str_detect(group, &quot;combined&quot;)) |&gt; pull(sample_size) # number in group 2
  sx = df |&gt; filter(str_detect(group, &quot;Low/medium tau&quot;)) |&gt; pull(sd) # sd of group 1
  sy = df |&gt; filter(str_detect(group, &quot;combined&quot;)) |&gt; pull(sd) # sd of group 2
  x_bar = df |&gt; filter(str_detect(group, &quot;Low/medium tau&quot;)) |&gt; pull(mean) # mean of group 1
  y_bar = df |&gt; filter(str_detect(group, &quot;combined&quot;)) |&gt; pull(mean) # mean of group 2

  combined_mean = (n * x_bar + m * y_bar) / (n + m)
  combined_sd =   sqrt(((n-1)*sx^2+(m-1)*sy^2)/(n+m-1)+(n*m*(x_bar-y_bar)^2)/((n+m)*(n+m-1)))
  combined_samplesize = n + m
  combined_ci_lower = combined_mean - 1.96*combined_sd
  combined_ci_upper = combined_mean + 1.96*combined_sd
  
  return (tibble(
    outcome = df |&gt; head(1) |&gt; pull(outcome),
    group = group,
    mean = combined_mean,
    sd = combined_sd,
    sample_size = combined_samplesize,
    ci_lower = combined_ci_lower,
    ci_upper = combined_ci_upper,
    time = 0))}</code></pre>
<div id="clinical-trials-pipeline" class="section level1">
<h1>Clinical Trials Pipeline</h1>
<p>In our quest to deepen the understanding of Alzheimer’s disease and
its treatment landscape, we have developed an innovative Shiny
application designed to visualize the clinical trials of Alzheimer’s
drugs across the United States. This interactive tool is a significant
stride in making complex trial data accessible, which labels all trials
on the map and has regional statistics based on zoom size. The following
screenshot offers a glimpse into the app’s capabilities, and the full
dashboard can be accessed [here].</p>
<p><img src="project_image/shiny_CT1.png" style="width:85%"></p>
</div>
<div id="trials-comparison" class="section level1">
<h1>Trials comparison</h1>
<p>We further evaluate and compare the performance of the two latest
promising drugs Lecanemab and Donanemab for their participants’
characteristics, treatment efficacy, and adverse events.</p>
<div id="participants-demographics" class="section level2">
<h2>Participants’ Demographics</h2>
<pre class="r"><code>sex_df=
  readxl::read_excel(&quot;data/newdrugdemographic.xlsx&quot;,sheet=&quot;Sex&quot;, range = &quot;A1:C5&quot;) |&gt; 
  janitor::clean_names()

race_df=
  readxl::read_excel(&quot;data/newdrugdemographic.xlsx&quot;,sheet=&quot;Race&quot;, range = &quot;A1:C9&quot;) |&gt; 
  janitor::clean_names()

sex_colors &lt;- c(&quot;Male&quot; = &quot;#a1afc9&quot;, &quot;Female&quot; = &quot;#edd1d8&quot;) 
race_colors &lt;- c(&quot;Black&quot; = &quot;#c2ccd0&quot;, &quot;Asian&quot; =&quot;#fcefe8&quot;, &quot;White&quot; = &quot;#e0eee8&quot;, &quot;Other or Missing&quot; = &quot;#eedeb0&quot;) 


p1 &lt;- sex_df |&gt; 
  plot_ly(x = ~drug, y = ~sex_prop, type = &quot;bar&quot;, color = ~sex, colors = sex_colors, legendgroup = &quot;sex&quot;) |&gt; 
  layout(barmode = &quot;stack&quot;,
         showlegend = TRUE) |&gt;
    add_annotations(
    text = &quot;Sex&quot;,
    x = 0.5,
    y = 1.05,
    xref = &quot;paper&quot;,
    yref = &quot;paper&quot;,
    showarrow = FALSE,
    font = list(size = 10)
  )

p2 &lt;- race_df |&gt; 
  mutate(race = fct_reorder(race, -race_prop)) |&gt; 
  plot_ly(x = ~drug, y = ~race_prop, type = &quot;bar&quot;, color = ~race, colors = race_colors, legendgroup = &quot;race&quot;) |&gt; 
  layout(barmode = &quot;stack&quot;,
         showlegend = TRUE) |&gt;
    add_annotations(
    text = &quot;Race&quot;,
    x = 0.5,
    y = 1.05,
    xref = &quot;paper&quot;,
    yref = &quot;paper&quot;,
    showarrow = FALSE,
    font = list(size = 10)
  )

subplot(p1, p2, nrows = 1, margin = 0.05) |&gt;
  layout(title = &quot;Distribution of Baseline Participants&#39; Sex and Race by Drug&quot;,
         yaxis = list(title = &quot;Percentage (%)&quot;))</code></pre>
<div class="plotly html-widget html-fill-item" id="htmlwidget-da7718a859d2f011158f" style="width:90%;height:345.6px;"></div>
<script type="application/json" data-for="htmlwidget-da7718a859d2f011158f">{"x":{"data":[{"x":["Lecanemab","Donanemab"],"y":[51.600000000000001,56.5],"legendgroup":"sex","type":"bar","name":"Female","marker":{"color":"rgba(237,209,216,1)","line":{"color":"rgba(237,209,216,1)"}},"textfont":{"color":"rgba(237,209,216,1)"},"error_y":{"color":"rgba(237,209,216,1)"},"error_x":{"color":"rgba(237,209,216,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Lecanemab","Donanemab"],"y":[48.399999999999999,43.5],"legendgroup":"sex","type":"bar","name":"Male","marker":{"color":"rgba(161,175,201,1)","line":{"color":"rgba(161,175,201,1)"}},"textfont":{"color":"rgba(161,175,201,1)"},"error_y":{"color":"rgba(161,175,201,1)"},"error_x":{"color":"rgba(161,175,201,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Lecanemab","Donanemab"],"y":[76.299999999999997,90],"legendgroup":"race","type":"bar","name":"White","marker":{"color":"rgba(224,238,232,1)","line":{"color":"rgba(224,238,232,1)"}},"textfont":{"color":"rgba(224,238,232,1)"},"error_y":{"color":"rgba(224,238,232,1)"},"error_x":{"color":"rgba(224,238,232,1)"},"xaxis":"x2","yaxis":"y2","frame":null},{"x":["Lecanemab","Donanemab"],"y":[17.100000000000001,7.2999999999999998],"legendgroup":"race","type":"bar","name":"Asian","marker":{"color":"rgba(252,239,232,1)","line":{"color":"rgba(252,239,232,1)"}},"textfont":{"color":"rgba(252,239,232,1)"},"error_y":{"color":"rgba(252,239,232,1)"},"error_x":{"color":"rgba(252,239,232,1)"},"xaxis":"x2","yaxis":"y2","frame":null},{"x":["Lecanemab","Donanemab"],"y":[2.2999999999999998,2.5],"legendgroup":"race","type":"bar","name":"Black","marker":{"color":"rgba(194,204,208,1)","line":{"color":"rgba(194,204,208,1)"}},"textfont":{"color":"rgba(194,204,208,1)"},"error_y":{"color":"rgba(194,204,208,1)"},"error_x":{"color":"rgba(194,204,208,1)"},"xaxis":"x2","yaxis":"y2","frame":null},{"x":["Lecanemab","Donanemab"],"y":[4.2999999999999998,0.20000000000000001],"legendgroup":"race","type":"bar","name":"Other or Missing","marker":{"color":"rgba(238,222,176,1)","line":{"color":"rgba(238,222,176,1)"}},"textfont":{"color":"rgba(238,222,176,1)"},"error_y":{"color":"rgba(238,222,176,1)"},"error_x":{"color":"rgba(238,222,176,1)"},"xaxis":"x2","yaxis":"y2","frame":null}],"layout":{"xaxis":{"domain":[0,0.45000000000000001],"automargin":true,"type":"category","categoryorder":"array","categoryarray":["Donanemab","Lecanemab"],"anchor":"y"},"xaxis2":{"domain":[0.55000000000000004,1],"automargin":true,"type":"category","categoryorder":"array","categoryarray":["Donanemab","Lecanemab"],"anchor":"y2"},"yaxis2":{"domain":[0,1],"automargin":true,"anchor":"x2"},"yaxis":{"domain":[0,1],"automargin":true,"anchor":"x","title":"Percentage (%)"},"annotations":[{"text":"Sex","x":0.22500000000000001,"y":1.05,"xref":"paper","yref":"paper","showarrow":false,"font":{"size":10}},{"text":"Race","x":0.77500000000000002,"y":1.05,"xref":"paper","yref":"paper","showarrow":false,"font":{"size":10}}],"shapes":[],"images":[],"margin":{"b":40,"l":60,"t":25,"r":10},"barmode":"stack","showlegend":true,"hovermode":"closest","title":"Distribution of Baseline Participants' Sex and Race by Drug"},"attrs":{"7100271e26af":{"x":{},"y":{},"legendgroup":"sex","color":{},"colors":["#a1afc9","#edd1d8"],"alpha_stroke":1,"sizes":[10,100],"spans":[1,20],"type":"bar"},"7100206d4dd1":{"x":{},"y":{},"legendgroup":"race","color":{},"colors":["#c2ccd0","#fcefe8","#e0eee8","#eedeb0"],"alpha_stroke":1,"sizes":[10,100],"spans":[1,20],"type":"bar"}},"source":"A","config":{"modeBarButtonsToAdd":["hoverclosest","hovercompare"],"showSendToCloud":false},"highlight":{"on":"plotly_click","persistent":false,"dynamic":false,"selectize":false,"opacityDim":0.20000000000000001,"selected":{"opacity":1},"debounce":0},"subplot":true,"shinyEvents":["plotly_hover","plotly_click","plotly_selected","plotly_relayout","plotly_brushed","plotly_brushing","plotly_clickannotation","plotly_doubleclick","plotly_deselect","plotly_afterplot","plotly_sunburstclick"],"base_url":"https://plot.ly"},"evals":[],"jsHooks":[]}</script>
<ul>
<li><p>From the plot, we can see that there are more female participants
in Donanemab’s clinical trial that in Lecanemab’s clinical
trial.</p></li>
<li><p>From the plot, we can also see there is more diversity in
Lecanemab’s clinical trial. Races other than white occupy a larger
proportion of participants in Lecanemab’s clinical trial than in
Donanemab’s clinical trial than that in Lecanemab’s clinical trial,
especially Asians.</p></li>
</ul>
<p>All trials participants took Alzheimer’s tests to evaluate their
stages at the start of study. CDR-SB (Clinical Dementia Rating Scale Sum
of Boxes), ADAS-Cog (Alzheimer’s Disease Assessment Scale - Cognitive
Subscale) and MMSE (Mini-mental state examination) were shown in the
plot, details of theses test scores were explained in next part.</p>
<pre class="r"><code>iADRS &lt;- read_excel(&quot;data/Donanemab_.xlsx&quot;, sheet = &quot;1&quot;)
CDR_SB &lt;- read_excel(&quot;data/Donanemab_.xlsx&quot;, sheet = &quot;2&quot;)
ADCS_iADL &lt;- read_excel(&quot;data/Donanemab_.xlsx&quot;, sheet = &quot;3&quot;)
ADAS_Cog13 &lt;- read_excel(&quot;data/Donanemab_.xlsx&quot;, sheet = &quot;4&quot;)
MMSE &lt;- read_excel(&quot;data/Donanemab_.xlsx&quot;, sheet = &quot;5&quot;)

lec_result &lt;- read_excel(&quot;data/Lecanemab.xlsx&quot;, sheet = &quot;result&quot;) |&gt;
  filter(time == 0,
         outcome %in% c(&quot;CDR-SB&quot;, &quot;ADAS-Cog14&quot;, &quot;MMSE&quot;)) |&gt;
  mutate(drug = &quot;Lecanemab&quot;,
         ci_lower = mean - 1.96*sd,
         ci_upper = mean + 1.96*sd) |&gt;
  select(drug, everything())

don_result = bind_rows(
  combine_mean_sd(CDR_SB |&gt; filter(time == 0, str_detect(group, &quot;Donanemab&quot;)), &quot;Donanemab&quot;),
  combine_mean_sd(CDR_SB |&gt; filter(time == 0, str_detect(group, &quot;Placebo&quot;)), &quot;Placebo&quot;),
  combine_mean_sd(ADAS_Cog13 |&gt; filter(time == 0, str_detect(group, &quot;Donanemab&quot;)), &quot;Donanemab&quot;),
  combine_mean_sd(ADAS_Cog13 |&gt; filter(time == 0, str_detect(group, &quot;Placebo&quot;)), &quot;Placebo&quot;),
  combine_mean_sd(MMSE |&gt; filter(time == 0, str_detect(group, &quot;Donanemab&quot;)), &quot;Donanemab&quot;),
  combine_mean_sd(MMSE |&gt; filter(time == 0, str_detect(group, &quot;Placebo&quot;)), &quot;Placebo&quot;)
  ) |&gt;
  mutate(drug = &quot;Donanemab&quot;) |&gt;
  select(drug, everything())


ggplot(bind_rows(lec_result, don_result) |&gt; filter (!(outcome %in% c(&quot;CDR-SB&quot;, &quot;MMSE&quot;) &amp; group == &quot;Placebo&quot;)), aes(x = as.factor(time), y = mean, fill = group, color = group)) +
  geom_point(position = position_dodge(0.9), size = 3, alpha = 0.7) +
  geom_errorbar(aes(ymin = ci_lower, ymax = ci_upper), position = position_dodge(0.9), width = 0.25) +
  facet_wrap(~outcome, scales = &quot;free_y&quot;) +
  labs(title = &quot;Mean with 95% CI at Baseline&quot;,
       x = &quot;Time&quot;,
       y = &quot;Mean&quot;) +
  theme_minimal()</code></pre>
<p><img src="Clinical_trials_files/figure-html/unnamed-chunk-4-1.png" width="90%" /></p>
</div>
<div id="treatment-evaluation" class="section level2">
<h2>Treatment evaluation</h2>
<p>The evaluated outcomes encompassed measures such as CDR-SB (Clinical
Dementia Rating Scale Sum of Boxes), ADAS-Cog (Alzheimer’s Disease
Assessment Scale - Cognitive Subscale), and various other clinical
assessments. These metrics collectively offer valuable insights into the
effectiveness of donanemab in comparison to the placebo, shedding light
on its impact on slowing the progression of Alzheimer’s disease over the
76-week (18 months) trial period.</p>
<p>In the trial of Donanemab, participants were categorized into two
groups based on tau biomarker levels in their cerebrospinal fluid (CSF):
those with low/medium tau (mild cognitive impairment or early
Alzheimer’s with lower tau levels) and those with high tau (early
Alzheimer’s with higher tau levels). Additionally, a combined population
included all trial participants, irrespective of tau levels. This
stratification aimed to evaluate the efficacy of donanemab across
different Alzheimer’s patient subgroups.</p>
<div id="cdr-sb" class="section level3">
<h3>CDR-SB</h3>
<p>The Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) is a widely
used assessment tool for evaluating the severity of dementia. It is a
composite score derived from the Clinical Dementia Rating (CDR) scale,
which is used to assess the cognitive and functional abilities of
individuals with dementia.</p>
<p>The CDR-SB incorporates ratings across six domains: memory,
orientation, judgment and problem solving, community affairs, home and
hobbies, and personal care. Each domain is rated on a scale from 0 (no
impairment) to 3 (severe impairment), and the total CDR-SB score ranges
from 0 to 18, with higher scores indicating greater clinical
impairment.</p>
<pre class="r"><code>Don_CDR_SB = read_excel(&quot;data/Donanemab.xlsx&quot;, sheet = &quot;result&quot;) |&gt;
  filter(outcome == &quot;CDR-SB&quot;,
         str_detect(group, &quot;combined&quot;))

Lec_CDR_SB = read_excel(&quot;data/Lecanemab.xlsx&quot;, sheet = &quot;result&quot;) |&gt;
  filter(outcome == &quot;CDR-SB&quot;)

CDR_SB_merge = bind_rows(Don_CDR_SB, Lec_CDR_SB) |&gt;
  mutate(group = case_match(
    group,
    &quot;Donanemab-combined&quot; ~ &quot;Donanemab-combined&quot;,
    &quot;Placebo-combined&quot; ~ &quot;Donanemab Placebo-combined&quot;,
    &quot;Lecanemab&quot; ~ &quot;Lecanemab&quot;,
    &quot;Placebo&quot; ~ &quot;Lecanemab Placebo&quot;))

ggplot(CDR_SB_merge, aes(x = as.factor(time), y = mean, fill = group, color = group)) +
  geom_point(position = position_dodge(0.9), size = 3, alpha = 0.7) +
  geom_errorbar(aes(ymin = ci_lower, ymax = ci_upper), position = position_dodge(0.9), width = 0.25) +
  labs(title = &quot;Mean with 95% CI over Time (CDR-SB)&quot;,
       x = &quot;Time&quot;,
       y = &quot;Mean&quot;) +
  theme_minimal() +
  theme(plot.title = element_text(hjust = 0.5))</code></pre>
<p><img src="Clinical_trials_files/figure-html/unnamed-chunk-5-1.png" width="90%" /></p>
<ul>
<li>The trial results demonstrated that both treatments slows the
clinical progression of Alzheimer compared to their placebo as measured
by the CDR-SB, indicating its potential efficacy in addressing the
symptoms and functional decline associated with early symptomatic
Alzheimer’s disease. Lecanemab shows adjusted mean change of 1.21 from
baseline to endpoint, while Donanemab shows 1.16 (95%CI: 0.97-1.35)
least square mean change.</li>
</ul>
</div>
<div id="adas-cog" class="section level3">
<h3>ADAS-Cog</h3>
<p>The ADAS-Cog, a primary cognitive outcome measure mandated by the FDA
for Alzheimer’s drug trials in the U.S., assesses language, memory,
praxis, and orientation. This test, taking 30-35 minutes, scores from
0-70, with higher scores indicating greater cognitive impairment.</p>
<pre class="r"><code>Don_ADAS_Cog  = read_excel(&quot;data/Donanemab.xlsx&quot;, sheet = &quot;result&quot;) |&gt;
  filter(outcome == &quot;ADAS-Cog13&quot;)

Lec_ADAS_Cog = read_excel(&quot;data/Lecanemab.xlsx&quot;, sheet = &quot;result&quot;) |&gt;
  filter(outcome == &quot;ADAS-Cog14&quot;)

ADAS_Cog_merge = bind_rows(Don_ADAS_Cog, Lec_ADAS_Cog) |&gt;
  mutate(group = case_match(
    group,
    &quot;Donanemab-combined&quot; ~ &quot;Donanemab (combined)&quot;,
    &quot;Placebo-combined&quot; ~ &quot;Donanemab Placebo (combined)&quot;,
    &quot;Lecanemab&quot; ~ &quot;Lecanemab&quot;,
    &quot;Placebo&quot; ~ &quot;Lecanemab Placebo&quot;,
    &quot;Donanemab-Low/medium tau&quot; ~ &quot;Donanemab (Low/medium tau)&quot;,
    &quot;Placebo-Low/medium tau&quot; ~ &quot;Donanemab Placebo (Low/medium tau)&quot;))

ggplot(ADAS_Cog_merge, aes(x = as.factor(time), y = mean, fill = group, color = group)) +
  geom_point(position = position_dodge(0.9), size = 3, alpha = 0.7) +
  geom_errorbar(aes(ymin = ci_lower, ymax = ci_upper), position = position_dodge(0.9), width = 0.25) +
  labs(title = &quot;Mean with 95% CI over Time (ADAS-Cog)&quot;,
       x = &quot;Time&quot;,
       y = &quot;Mean&quot;) +
  theme_minimal() +
  theme(plot.title = element_text(hjust = 0.5))</code></pre>
<p><img src="Clinical_trials_files/figure-html/unnamed-chunk-6-1.png" width="90%" /></p>
<ul>
<li>A more pronounced reduction in the mean change from baseline to
endpoint in the treatment group, as compared to the placebo, was
observed for both Lecanemab (4.14 adjusted mean change) and Donanemab
(3.17 LSM for low/medium tau, 5.46 LSM for combined). This suggests a
potential positive impact of these drugs on cognitive function in
Alzheimer’s patients, with varying efficacy across different stages of
the disease.</li>
</ul>
</div>
</div>
<div id="survival-analysis" class="section level2">
<h2>Survival Analysis</h2>
<p>The Phase III trials of Lecanemab and Donanemab both use cumulative
hazard ratio to indicate the risk of progression assessed using CDR-SB
score. The hazard plot for Donanemab is as following</p>
<pre class="r"><code>Don_KM = 
  read_excel(&quot;./Data/Donanemab.xlsx&quot;, sheet = &quot;K-M&quot;, range = &quot;A1:D16&quot;) |&gt;
  janitor::clean_names()

plot_ly(Don_KM |&gt;
                 filter(test == &quot;CDR-SB&quot;) |&gt;
                 pivot_longer(
                   donanemab:placebo,
                   names_to = &quot;drug&quot;,
                   values_to = &quot;ratio&quot;
                 ), x = ~time, y = ~ratio, color = ~drug, line = list(shape = &quot;hv&quot;), colors = &quot;viridis&quot;) |&gt;
  layout(title = &quot;Hazard Plot for Donanemab&quot;,
             xaxis = list(title = &quot;Days from First Infusion&quot;),
             yaxis = list(title = &quot;Percentage of Participants Progression&quot;))</code></pre>
<div class="plotly html-widget html-fill-item" id="htmlwidget-54e02fbfe587b23c0e19" style="width:90%;height:345.6px;"></div>
<script type="application/json" data-for="htmlwidget-54e02fbfe587b23c0e19">{"x":{"visdat":{"7100277622a5":["function () ","plotlyVisDat"]},"cur_data":"7100277622a5","attrs":{"7100277622a5":{"x":{},"y":{},"line":{"shape":"hv"},"color":{},"colors":"viridis","alpha_stroke":1,"sizes":[10,100],"spans":[1,20]}},"layout":{"margin":{"b":40,"l":60,"t":25,"r":10},"title":"Hazard Plot for Donanemab","xaxis":{"domain":[0,1],"automargin":true,"title":"Days from First Infusion"},"yaxis":{"domain":[0,1],"automargin":true,"title":"Percentage of Participants Progression"},"hovermode":"closest","showlegend":true},"source":"A","config":{"modeBarButtonsToAdd":["hoverclosest","hovercompare"],"showSendToCloud":false},"data":[{"x":[0,60,120,180,240,360,480,540],"y":[0,0,0.035000000000000003,0.070000000000000007,0.078,0.154,0.26300000000000001,0.26300000000000001],"line":{"color":"rgba(68,1,84,1)","shape":"hv"},"type":"scatter","mode":"markers+lines","name":"donanemab","marker":{"color":"rgba(68,1,84,1)","line":{"color":"rgba(68,1,84,1)"}},"textfont":{"color":"rgba(68,1,84,1)"},"error_y":{"color":"rgba(68,1,84,1)"},"error_x":{"color":"rgba(68,1,84,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":[0,60,120,180,240,360,480,540],"y":[0,0,0.081000000000000003,0.14999999999999999,0.17000000000000001,0.246,0.38700000000000001,0.38700000000000001],"line":{"color":"rgba(253,231,37,1)","shape":"hv"},"type":"scatter","mode":"markers+lines","name":"placebo","marker":{"color":"rgba(253,231,37,1)","line":{"color":"rgba(253,231,37,1)"}},"textfont":{"color":"rgba(253,231,37,1)"},"error_y":{"color":"rgba(253,231,37,1)"},"error_x":{"color":"rgba(253,231,37,1)"},"xaxis":"x","yaxis":"y","frame":null}],"highlight":{"on":"plotly_click","persistent":false,"dynamic":false,"selectize":false,"opacityDim":0.20000000000000001,"selected":{"opacity":1},"debounce":0},"shinyEvents":["plotly_hover","plotly_click","plotly_selected","plotly_relayout","plotly_brushed","plotly_brushing","plotly_clickannotation","plotly_doubleclick","plotly_deselect","plotly_afterplot","plotly_sunburstclick"],"base_url":"https://plot.ly"},"evals":[],"jsHooks":[]}</script>
<ul>
<li>The hazard ratio for the combined group of Donanemab was found to be
0.623 with a 95% confidence interval of 0.519 to 0.748, indicating a
significant reduction in the risk associated with the progression of
Alzheimer’s disease as measured by the CDR-SB score. In comparison,
Lecanemab demonstrated a hazard ratio of 0.69, also suggesting a reduced
risk, albeit to a slightly lesser extent than Donanemab. These results
indicate that both drugs are effective in slowing the progression of
Alzheimer’s disease, with Donanemab showing a marginally higher efficacy
in this regard.</li>
</ul>
</div>
<div id="adverse-events" class="section level2">
<h2>Adverse Events</h2>
<div id="general-overview" class="section level3">
<h3>General Overview</h3>
<p>As we progress in our comprehensive exploration of Alzheimer’s
disease and its treatment options, we now turn our focus to a critical
aspect of drug evaluation: the analysis of adverse events associated
with the two promising drugs.</p>
<pre class="r"><code>lec_safety = read_excel(&quot;./Data/Lecanemab.xlsx&quot;, sheet = &quot;safety&quot;, range = &quot;A1:C5&quot;) |&gt;
  janitor::clean_names()

don_safety = read_excel(&quot;./Data/Donanemab.xlsx&quot;, sheet = &quot;safety&quot;, range = &quot;A1:C5&quot;) |&gt;
  janitor::clean_names()

merge_safety = left_join(lec_safety, don_safety, by = &quot;events&quot;)</code></pre>
<pre class="r"><code>plot_ly(merge_safety |&gt;
  mutate(events = fct_reorder(events, -lecanemab)) |&gt;
  pivot_longer(
    lecanemab:donanemab_placebo,
    names_to = &quot;drug&quot;,
    values_to = &quot;cases&quot;
  ), 
  x = ~events, y = ~cases, color = ~drug, type = &#39;bar&#39;, colors = &quot;viridis&quot;)  |&gt;
  layout(title = &quot;Barplot for Adverse Events&quot;,
             xaxis = list(title = &quot;Adverse Event&quot;),
             yaxis = list(title = &quot;Number of participants&quot;))</code></pre>
<div class="plotly html-widget html-fill-item" id="htmlwidget-d04cd2376695903ec2ad" style="width:90%;height:345.6px;"></div>
<script type="application/json" data-for="htmlwidget-d04cd2376695903ec2ad">{"x":{"visdat":{"710049bc5fe1":["function () ","plotlyVisDat"]},"cur_data":"710049bc5fe1","attrs":{"710049bc5fe1":{"x":{},"y":{},"color":{},"colors":"viridis","alpha_stroke":1,"sizes":[10,100],"spans":[1,20],"type":"bar"}},"layout":{"margin":{"b":40,"l":60,"t":25,"r":10},"title":"Barplot for Adverse Events","xaxis":{"domain":[0,1],"automargin":true,"title":"Adverse Event","type":"category","categoryorder":"array","categoryarray":["Participants with ≥1 AEs","Participants with ≥1 serious Aes","Study discontinuations due to AEs","Death"]},"yaxis":{"domain":[0,1],"automargin":true,"title":"Number of participants"},"hovermode":"closest","showlegend":true},"source":"A","config":{"modeBarButtonsToAdd":["hoverclosest","hovercompare"],"showSendToCloud":false},"data":[{"x":["Participants with ≥1 AEs","Participants with ≥1 serious Aes","Study discontinuations due to AEs","Death"],"y":[759,148,69,16],"type":"bar","name":"donanemab","marker":{"color":"rgba(68,1,84,1)","line":{"color":"rgba(68,1,84,1)"}},"textfont":{"color":"rgba(68,1,84,1)"},"error_y":{"color":"rgba(68,1,84,1)"},"error_x":{"color":"rgba(68,1,84,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Participants with ≥1 AEs","Participants with ≥1 serious Aes","Study discontinuations due to AEs","Death"],"y":[718,138,32,10],"type":"bar","name":"donanemab_placebo","marker":{"color":"rgba(49,104,142,1)","line":{"color":"rgba(49,104,142,1)"}},"textfont":{"color":"rgba(49,104,142,1)"},"error_y":{"color":"rgba(49,104,142,1)"},"error_x":{"color":"rgba(49,104,142,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Participants with ≥1 AEs","Participants with ≥1 serious Aes","Study discontinuations due to AEs","Death"],"y":[798,126,62,6],"type":"bar","name":"lecanemab","marker":{"color":"rgba(53,183,121,1)","line":{"color":"rgba(53,183,121,1)"}},"textfont":{"color":"rgba(53,183,121,1)"},"error_y":{"color":"rgba(53,183,121,1)"},"error_x":{"color":"rgba(53,183,121,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Participants with ≥1 AEs","Participants with ≥1 serious Aes","Study discontinuations due to AEs","Death"],"y":[735,101,26,7],"type":"bar","name":"lecanemab_placebo","marker":{"color":"rgba(253,231,37,1)","line":{"color":"rgba(253,231,37,1)"}},"textfont":{"color":"rgba(253,231,37,1)"},"error_y":{"color":"rgba(253,231,37,1)"},"error_x":{"color":"rgba(253,231,37,1)"},"xaxis":"x","yaxis":"y","frame":null}],"highlight":{"on":"plotly_click","persistent":false,"dynamic":false,"selectize":false,"opacityDim":0.20000000000000001,"selected":{"opacity":1},"debounce":0},"shinyEvents":["plotly_hover","plotly_click","plotly_selected","plotly_relayout","plotly_brushed","plotly_brushing","plotly_clickannotation","plotly_doubleclick","plotly_deselect","plotly_afterplot","plotly_sunburstclick"],"base_url":"https://plot.ly"},"evals":[],"jsHooks":[]}</script>
<ul>
<li><p>The Lecanemab group experienced a 0.7% death rate (6 cases)
compared to 0.8% (7 cases) in the placebo group, with no deaths linked
to Lecanemab or ARIA. Serious adverse events were slightly higher in the
Lecanemab group at 14.0% (126 cases) versus 11.3% (101 cases) in the
placebo.</p></li>
<li><p>For Donanemab, the death rate was 1.9% (16 cases) in the
treatment group against 1.1% (10 cases) in the placebo, with serious
adverse events at 17.4% (148 cases) for Donanemab and 15.8% (138 cases)
for the placebo. These results suggest a similar safety profile for both
drugs compared to their respective placebo groups.</p></li>
</ul>
<pre class="r"><code>safety_test = function(a, b, c, d, n1, n2){
  RD = round(a/n1 - b/n2, 4)
  RR = round((a/n1)/(b/n2), 4)
  OR = round((a*d)/(b*c), 4)
  Chis = round(prop.test(x = c(a, b), n = c(c, d), alternative = &quot;two.sided&quot;, correct = FALSE)$statistic, 4)
  p_value = round(prop.test(x = c(a, b), n = c(n1, n2), alternative = &quot;two.sided&quot;, correct = FALSE)$p.value, 6)
  return (tibble(Risk_Diff = RD, Risk_Ratio = RR, Odds_Ratio = OR, Xsquared = Chis, P.value = p_value))
  }</code></pre>
<pre class="r"><code>lec_safety_test = safety_test(126, 101, 772, 796, 898, 897)
don_safety_test = safety_test(148, 138, 705, 736, 853, 874)
comp_safety_test = safety_test(126, 148, 772, 705, 898, 853)
safety_merge = bind_rows(lec_safety_test, don_safety_test, comp_safety_test) |&gt;
  mutate(Test = c(&quot;Lec vs Placebo&quot;, &quot;Don vs Placebo&quot;, &quot;Lec vs Don&quot;)) |&gt;
  select(Test, everything())

kable(safety_merge)</code></pre>
<table>
<thead>
<tr class="header">
<th align="left">Test</th>
<th align="right">Risk_Diff</th>
<th align="right">Risk_Ratio</th>
<th align="right">Odds_Ratio</th>
<th align="right">Xsquared</th>
<th align="right">P.value</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">Lec vs Placebo</td>
<td align="right">0.0277</td>
<td align="right">1.2461</td>
<td align="right">1.2863</td>
<td align="right">4.1774</td>
<td align="right">0.077332</td>
</tr>
<tr class="even">
<td align="left">Don vs Placebo</td>
<td align="right">0.0156</td>
<td align="right">1.0989</td>
<td align="right">1.1196</td>
<td align="right">1.1387</td>
<td align="right">0.382920</td>
</tr>
<tr class="odd">
<td align="left">Lec vs Don</td>
<td align="right">-0.0332</td>
<td align="right">0.8087</td>
<td align="right">0.7775</td>
<td align="right">5.3225</td>
<td align="right">0.056015</td>
</tr>
</tbody>
</table>
<p>In our statistical analysis of serious adverse events associated with
Lecanemab, Donanemab, and their placebos, we have identified key
findings. With a significance level set at 0.1, our results indicate a
significant difference in serious adverse events between Lecanemab and
its placebo, suggesting a higher risk associated with Lecanemab. In
contrast, Donanemab did not show a significant difference in serious
adverse events compared to its placebo, implying a potentially safer
profile. Additionally, a significant difference was observed between
Lecanemab and Donanemab, highlighting distinct safety profiles for these
drugs.</p>
<p>Then, we further investigate the differences of specific adverse
events for two drugs.</p>
<pre class="r"><code>lec_ae = read_excel(&quot;./Data/Lecanemab.xlsx&quot;, sheet = &quot;AE&quot;, range = &quot;A1:C10&quot;) |&gt;
  janitor::clean_names()

don_ae = read_excel(&quot;./Data/Donanemab.xlsx&quot;, sheet = &quot;AE&quot;, range = &quot;A1:C10&quot;) |&gt;
  janitor::clean_names()

merge_ae = left_join(lec_ae, don_ae, by = &quot;ae&quot;)</code></pre>
<pre class="r"><code>plot_ly(merge_ae |&gt;
  mutate(ae = fct_reorder(ae, donanemab)) |&gt;
  pivot_longer(
    lecanemab:donanemab_placebo,
    names_to = &quot;drug&quot;,
    values_to = &quot;cases&quot;
  ), 
  x = ~ae, y = ~cases, color = ~drug, type = &#39;bar&#39;, colors = &quot;viridis&quot;)  |&gt;
  layout(title = &quot;Barplot for Adverse Events&quot;,
             xaxis = list(title = &quot;Adverse Event&quot;),
             yaxis = list(title = &quot;Number of participants&quot;))</code></pre>
<div class="plotly html-widget html-fill-item" id="htmlwidget-82e816fc47f72a5ea695" style="width:90%;height:345.6px;"></div>
<script type="application/json" data-for="htmlwidget-82e816fc47f72a5ea695">{"x":{"visdat":{"710067a54fc6":["function () ","plotlyVisDat"]},"cur_data":"710067a54fc6","attrs":{"710067a54fc6":{"x":{},"y":{},"color":{},"colors":"viridis","alpha_stroke":1,"sizes":[10,100],"spans":[1,20],"type":"bar"}},"layout":{"margin":{"b":40,"l":60,"t":25,"r":10},"title":"Barplot for Adverse Events","xaxis":{"domain":[0,1],"automargin":true,"title":"Adverse Event","type":"category","categoryorder":"array","categoryarray":["Diarrhea","Urinary tract infection","Arrthralgia","Dizziness","Infusion-related reaction","Fall","Headache","ARIA-H","ARIA-E"]},"yaxis":{"domain":[0,1],"automargin":true,"title":"Number of participants"},"hovermode":"closest","showlegend":true},"source":"A","config":{"modeBarButtonsToAdd":["hoverclosest","hovercompare"],"showSendToCloud":false},"data":[{"x":["Infusion-related reaction","ARIA-E","ARIA-H","Headache","Fall","Urinary tract infection","Arrthralgia","Dizziness","Diarrhea"],"y":[74,205,168,119,114,45,49,53,43],"type":"bar","name":"donanemab","marker":{"color":"rgba(68,1,84,1)","line":{"color":"rgba(68,1,84,1)"}},"textfont":{"color":"rgba(68,1,84,1)"},"error_y":{"color":"rgba(68,1,84,1)"},"error_x":{"color":"rgba(68,1,84,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Infusion-related reaction","ARIA-E","ARIA-H","Headache","Fall","Urinary tract infection","Arrthralgia","Dizziness","Diarrhea"],"y":[4,17,65,86,110,59,42,48,50],"type":"bar","name":"donanemab_placebo","marker":{"color":"rgba(49,104,142,1)","line":{"color":"rgba(49,104,142,1)"}},"textfont":{"color":"rgba(49,104,142,1)"},"error_y":{"color":"rgba(49,104,142,1)"},"error_x":{"color":"rgba(49,104,142,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Infusion-related reaction","ARIA-E","ARIA-H","Headache","Fall","Urinary tract infection","Arrthralgia","Dizziness","Diarrhea"],"y":[237,113,155,100,93,78,53,49,48],"type":"bar","name":"lecanemab","marker":{"color":"rgba(53,183,121,1)","line":{"color":"rgba(53,183,121,1)"}},"textfont":{"color":"rgba(53,183,121,1)"},"error_y":{"color":"rgba(53,183,121,1)"},"error_x":{"color":"rgba(53,183,121,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Infusion-related reaction","ARIA-E","ARIA-H","Headache","Fall","Urinary tract infection","Arrthralgia","Dizziness","Diarrhea"],"y":[66,15,81,73,86,82,62,46,58],"type":"bar","name":"lecanemab_placebo","marker":{"color":"rgba(253,231,37,1)","line":{"color":"rgba(253,231,37,1)"}},"textfont":{"color":"rgba(253,231,37,1)"},"error_y":{"color":"rgba(253,231,37,1)"},"error_x":{"color":"rgba(253,231,37,1)"},"xaxis":"x","yaxis":"y","frame":null}],"highlight":{"on":"plotly_click","persistent":false,"dynamic":false,"selectize":false,"opacityDim":0.20000000000000001,"selected":{"opacity":1},"debounce":0},"shinyEvents":["plotly_hover","plotly_click","plotly_selected","plotly_relayout","plotly_brushed","plotly_brushing","plotly_clickannotation","plotly_doubleclick","plotly_deselect","plotly_afterplot","plotly_sunburstclick"],"base_url":"https://plot.ly"},"evals":[],"jsHooks":[]}</script>
<p>The barplot clearly shows notable differences in specific adverse
events (such as Infusion-related reactions, ARIA-E/ARIA-H, Urinary tract
infections, and Headaches) between the treatment and placebo groups. To
further evaluate and quantify these observed differences, we will
proceed with a detailed statistical tests to provide a more definitive
understanding of the significance of these adverse events.</p>
</div>
<div id="lecanemab-vs-placebo" class="section level3">
<h3>Lecanemab vs Placebo</h3>
<pre class="r"><code># test = lec_ae |&gt;
#   mutate(p = lecanemab_placebo/sum(lecanemab_placebo))
# chisq.test(test$lecanemab, p = test$p, correct = FALSE) \
lec_ae_result = lec_ae |&gt;
  mutate(testresult = map2(lecanemab, lecanemab_placebo, \(a, b) safety_test(a, b, 898-a, 897-b, 898, 897))) |&gt;
  rename(Adverse_Effect = ae) |&gt;
  unnest(testresult) |&gt;
  select(-lecanemab, -lecanemab_placebo)

kable(lec_ae_result)</code></pre>
<table>
<colgroup>
<col width="34%" />
<col width="13%" />
<col width="14%" />
<col width="14%" />
<col width="11%" />
<col width="11%" />
</colgroup>
<thead>
<tr class="header">
<th align="left">Adverse_Effect</th>
<th align="right">Risk_Diff</th>
<th align="right">Risk_Ratio</th>
<th align="right">Odds_Ratio</th>
<th align="right">Xsquared</th>
<th align="right">P.value</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">Infusion-related reaction</td>
<td align="right">0.1903</td>
<td align="right">3.5869</td>
<td align="right">4.5144</td>
<td align="right">177.2332</td>
<td align="right">0.000000</td>
</tr>
<tr class="even">
<td align="left">ARIA-E</td>
<td align="right">0.1091</td>
<td align="right">7.5249</td>
<td align="right">8.4642</td>
<td align="right">94.4143</td>
<td align="right">0.000000</td>
</tr>
<tr class="odd">
<td align="left">ARIA-H</td>
<td align="right">0.0823</td>
<td align="right">1.9114</td>
<td align="right">2.1016</td>
<td align="right">36.1979</td>
<td align="right">0.000000</td>
</tr>
<tr class="even">
<td align="left">Headache</td>
<td align="right">0.0300</td>
<td align="right">1.3683</td>
<td align="right">1.4145</td>
<td align="right">5.7372</td>
<td align="right">0.031416</td>
</tr>
<tr class="odd">
<td align="left">Fall</td>
<td align="right">0.0077</td>
<td align="right">1.0802</td>
<td align="right">1.0895</td>
<td align="right">0.3691</td>
<td align="right">0.586741</td>
</tr>
<tr class="even">
<td align="left">Urinary tract infection</td>
<td align="right">-0.0046</td>
<td align="right">0.9502</td>
<td align="right">0.9454</td>
<td align="right">0.1396</td>
<td align="right">0.734818</td>
</tr>
<tr class="odd">
<td align="left">Arrthralgia</td>
<td align="right">-0.0101</td>
<td align="right">0.8539</td>
<td align="right">0.8447</td>
<td align="right">0.8755</td>
<td align="right">0.382293</td>
</tr>
<tr class="even">
<td align="left">Dizziness</td>
<td align="right">0.0033</td>
<td align="right">1.0640</td>
<td align="right">1.0677</td>
<td align="right">0.1080</td>
<td align="right">0.756031</td>
</tr>
<tr class="odd">
<td align="left">Diarrhea</td>
<td align="right">-0.0112</td>
<td align="right">0.8267</td>
<td align="right">0.8169</td>
<td align="right">1.1504</td>
<td align="right">0.313832</td>
</tr>
</tbody>
</table>
<ul>
<li>The statistical tests reveals significant differences in the
incidence of infusion-related reactions, ARIA-E/ARIA-H, and headaches
between the Lecanemab and placebo groups. These findings are consistent
with the most common side effects listed on the Lecanemab website,
validating our results. This highlights the need for careful monitoring
of these specific adverse events when considering Lecanemab for
Alzheimer’s treatment, ensuring informed decision-making and optimized
patient care.</li>
</ul>
</div>
<div id="donanemab-vs-placebo" class="section level3">
<h3>Donanemab vs Placebo</h3>
<pre class="r"><code># test = don_ae |&gt;
#   mutate(p = donanemab_placebo/sum(donanemab_placebo))
# chisq.test(test$donanemab, p = test$p, correct = FALSE)

don_ae_result = don_ae |&gt;
  mutate(testresult = map2(donanemab, donanemab_placebo, \(a, b) safety_test(a, b, 853-a, 874-b, 853, 874))) |&gt;
  rename(Adverse_Effect = ae) |&gt;
  unnest(testresult) |&gt;
  select(-donanemab, -donanemab_placebo)

kable(don_ae_result)</code></pre>
<table>
<colgroup>
<col width="34%" />
<col width="13%" />
<col width="14%" />
<col width="14%" />
<col width="11%" />
<col width="11%" />
</colgroup>
<thead>
<tr class="header">
<th align="left">Adverse_Effect</th>
<th align="right">Risk_Diff</th>
<th align="right">Risk_Ratio</th>
<th align="right">Odds_Ratio</th>
<th align="right">Xsquared</th>
<th align="right">P.value</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">Infusion-related reaction</td>
<td align="right">0.0822</td>
<td align="right">18.9555</td>
<td align="right">20.6611</td>
<td align="right">74.5253</td>
<td align="right">0.000000</td>
</tr>
<tr class="even">
<td align="left">ARIA-E</td>
<td align="right">0.2209</td>
<td align="right">12.3557</td>
<td align="right">15.9482</td>
<td align="right">258.0030</td>
<td align="right">0.000000</td>
</tr>
<tr class="odd">
<td align="left">ARIA-H</td>
<td align="right">0.1226</td>
<td align="right">2.6482</td>
<td align="right">3.0525</td>
<td align="right">76.6319</td>
<td align="right">0.000000</td>
</tr>
<tr class="even">
<td align="left">Headache</td>
<td align="right">0.0411</td>
<td align="right">1.4178</td>
<td align="right">1.4855</td>
<td align="right">9.1550</td>
<td align="right">0.008271</td>
</tr>
<tr class="odd">
<td align="left">Fall</td>
<td align="right">0.0078</td>
<td align="right">1.0619</td>
<td align="right">1.0714</td>
<td align="right">0.3132</td>
<td align="right">0.630088</td>
</tr>
<tr class="even">
<td align="left">Urinary tract infection</td>
<td align="right">-0.0148</td>
<td align="right">0.7815</td>
<td align="right">0.7693</td>
<td align="right">1.8867</td>
<td align="right">0.197644</td>
</tr>
<tr class="odd">
<td align="left">Arrthralgia</td>
<td align="right">0.0094</td>
<td align="right">1.1954</td>
<td align="right">1.2073</td>
<td align="right">0.8524</td>
<td align="right">0.382567</td>
</tr>
<tr class="even">
<td align="left">Dizziness</td>
<td align="right">0.0072</td>
<td align="right">1.1314</td>
<td align="right">1.1401</td>
<td align="right">0.4621</td>
<td align="right">0.523000</td>
</tr>
<tr class="odd">
<td align="left">Diarrhea</td>
<td align="right">-0.0068</td>
<td align="right">0.8812</td>
<td align="right">0.8749</td>
<td align="right">0.4388</td>
<td align="right">0.531494</td>
</tr>
</tbody>
</table>
<ul>
<li>The test for comparing Donanemab and its placebo group has similarly
identified significant differences in the occurrence of infusion-related
reactions, ARIA-E/ARIA-H, and headaches. This parallel finding with
Donanemab, mirroring the results observed with Lecanemab, underscores
the importance of these specific adverse events in the context of
Alzheimer’s disease treatments.</li>
</ul>
</div>
<div id="lecanemab-vs-donanemab" class="section level3">
<h3>Lecanemab vs Donanemab</h3>
<pre class="r"><code># test = don_ae |&gt;
#   mutate(p = donanemab_placebo/sum(donanemab_placebo))
# chisq.test(lec_ae$lecanemab, p = test$p, correct = FALSE) 
com_ae =  don_ae |&gt;
  mutate(lecanemab = lec_ae$lecanemab) |&gt;
  select(-donanemab_placebo)

com_ae_test = com_ae |&gt;
  mutate(testresult = map2(lecanemab, donanemab, \(a, b) safety_test(a, b, 898-a, 853-b, 898, 853))) |&gt;
  rename(Adverse_Effect = ae) |&gt;
  unnest(testresult) |&gt;
  select(-donanemab, -lecanemab) |&gt;
  filter(P.value &lt; 0.05)

kable(com_ae_test)</code></pre>
<table>
<colgroup>
<col width="34%" />
<col width="13%" />
<col width="14%" />
<col width="14%" />
<col width="11%" />
<col width="11%" />
</colgroup>
<thead>
<tr class="header">
<th align="left">Adverse_Effect</th>
<th align="right">Risk_Diff</th>
<th align="right">Risk_Ratio</th>
<th align="right">Odds_Ratio</th>
<th align="right">Xsquared</th>
<th align="right">P.value</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">Infusion-related reaction</td>
<td align="right">0.1772</td>
<td align="right">3.0422</td>
<td align="right">3.7744</td>
<td align="right">146.6853</td>
<td align="right">0.000000</td>
</tr>
<tr class="even">
<td align="left">ARIA-E</td>
<td align="right">-0.1145</td>
<td align="right">0.5236</td>
<td align="right">0.4550</td>
<td align="right">61.1095</td>
<td align="right">0.000000</td>
</tr>
<tr class="odd">
<td align="left">Urinary tract infection</td>
<td align="right">0.0341</td>
<td align="right">1.6465</td>
<td align="right">1.7080</td>
<td align="right">9.0587</td>
<td align="right">0.005251</td>
</tr>
</tbody>
</table>
<ul>
<li>In our comparative analysis of Lecanemab and Donanemab, we found
notable differences in specific adverse events. Lecanemab showed a
higher proportion of infusion-related reactions and urinary tract
infections, while Donanemab exhibited a higher incidence of ARIA-E.
These results highlight the distinct safety profiles of each drug,
emphasizing the need for tailored monitoring strategies based on the
unique risks associated with each treatment in managing Alzheimer’s
disease.</li>
</ul>
</div>
</div>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->
<script>
$(document).ready(function () {
  window.initializeCodeFolding("hide" === "show");
});
</script>

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
